Women who started menstruating at the age of 11 or younger, or entered menopause before 47, face a higher risk of heart disease and stroke, according to a study published Tuesday. Miscarriage, stillbirth, undergoing a hysterectomy, and bearing children at a young age were also associated with elevated odds of cardiovascular problems later in life, researchers found.
Adapsyn Bioscience Inc., a biotechnology company focused on the discovery and development of novel medicines derived from evolved small molecule natural products, announced that it has completed a round of financing that was co-funded by Pfizer R&D Innovate and Genesys Capital. In addition, the company has announced a research collaboration with Pfizer Inc.
Natural Cycles, a contraceptive app that became certified in the EU as a form of birth control, has been hit with a complaint after being blamed for causing 37 unwanted pregnancies
NHS officials have surmised that a system that identifies seriously ill patients would save approximately 2,000 lives a year. They have also estimated that 627,000 ‘bed days’ could be saved as a result.
If 2017 was about ransomware attacks, 2018 will be about cyber attacks on the Internet of Things (aka medical devices).
Mount Sinai researchers have discovered that normal immune cells called macrophages, which reside in healthy breast tissue surrounding milk ducts, play a major role in helping early breast cancer cells leave the breast for other parts of the body, potentially creating metastasis before a tumor has even developed, according to a study published in Nature Communications.
Global Blood Therapeutics, Inc. (GBT) (GBT) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to voxelotor (previously called GBT440) for the treatment of sickle cell disease (SCD). Voxelotor is being developed as a disease-modifying therapy for SCD and previously received European Medicines Agency (EMA) Priority Medicines (PRIME) designation for the treatment of SCD.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) has approved the use of TRISENOX® (arsenic trioxide) injection in combination with tretinoin for the treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. The approval was based on a Priority Review by the FDA on data from published scientific literature and a review of Teva’s global safety database for arsenic trioxide
Women attempting pregnancy may experience difficulty or delays in conceiving when they have moderate or severe iodine deficiency, according to findings published in Human Reproduction.
According to the Frost & Sullivan study, the total revenue of the global cloud-based medical imaging informatics market is expected to remain on a very strong growth trajectory over the next few years, growing from $285.4 million in 2016 to $830.5 million in 2021. That's a significant compound annual growth rate of 23.8 percent.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.